Xenetic Biosciences Inc
$ 3.00
0.00%
11 Jun - close price
- Market Cap 6,873,400 USD
- Current Price $ 3.00
- High / Low $ 3.12 / 3.00
- Stock P/E N/A
- Book Value 3.23
- EPS -1.19
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.37 %
- 52 Week High 13.93
- 52 Week Low 1.90
About
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
Analyst Target Price
$40.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-12 | 2025-11-12 | 2025-08-12 | 2025-05-13 | 2025-03-19 | 2024-11-12 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-10 | 2023-08-11 |
| Reported EPS | -0.1992 | -0.22 | -0.33 | -0.45 | -0.59 | -0.68 | -0.28 | -0.83 | -0.78 | -0.77 | -0.69 | -0.69 |
| Estimated EPS | None | -0.52 | -0.84 | -0.79 | -0.72 | -0.2 | -0.14 | -0.83 | -0.79 | -0.87 | -1.12 | -1.13 |
| Surprise | 0 | 0.3 | 0.51 | 0.34 | 0.13 | -0.48 | -0.14 | 0 | 0.01 | 0.1 | 0.43 | 0.44 |
| Surprise Percentage | None% | 57.6923% | 60.7143% | 43.038% | 18.0556% | -240% | -100% | 0% | 1.2658% | 11.4943% | 38.3929% | 38.9381% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XBIO
2026-06-05 11:09:00
Xenetic Biosciences, Inc. announced that its partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory clinical study. This study will combine systemic DNase I with anti-CD19 CAR T cells for large B-cell lymphoma (LBCL) patients, following positive preclinical results showing improved CAR T cell efficacy. The trial will enroll 12 LBCL patients to evaluate clinical efficacy and biomarker response at the Tel-Aviv Sourasky Medical Center.
2026-06-05 09:40:03
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced that its collaboration partner PerImmune Ltd. received approval from the Israeli Ministry of Health and an Institutional Review Board to conduct an exploratory clinical study. This study will evaluate systemic recombinant human DNase I in combination with anti-CD19 CAR T cells in patients with large B-cell lymphoma (LBCL). The approval follows positive preclinical results demonstrating enhanced anti-tumor activity of CAR T cells when combined with DNase I.
2026-06-04 12:40:51
Xenetic Biosciences, Inc. announced that its collaboration partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory clinical study. This study will combine systemic DNase I with anti-CD19 CAR T cells for large B-cell lymphoma (LBCL) patients, following positive preclinical results showing enhanced anti-tumor activity. The investigator-initiated study, led by Dr. Ron Ram, will take place at Tel-Aviv Sourasky Medical Center and aims to improve CAR T cell efficacy by mitigating the negative effects of cell-free chromatin and neutrophil extracellular traps.
2026-06-04 12:39:36
Xenetic Biosciences' partner, PeriNess, has received approval from the Israeli Ministry of Health to conduct an exploratory clinical study combining systemic DNase I with anti-CD19 CAR T cells for large B-cell lymphoma (LBCL) patients. The trial, to be conducted at Tel-Aviv Sourasky Medical Center, will treat 12 patients to evaluate response rates, disease control, and overall survival. This approval follows positive preclinical data suggesting DNase I enhances CAR T cell activity by mitigating negative effects of cell-free chromatin and neutrophil extracellular traps (NETs) in the tumor microenvironment.
2026-06-02 21:09:23
Xenetic Biosciences announced positive preclinical data at ASCO 2026, showing that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. The findings demonstrate DNase I's potential as a transformative adjunct therapy for CAR-T treatment by degrading immunosuppressive extracellular DNA and NETs, improving tumor control and prolonging survival. These results support the continued clinical development of DNase I to augment CAR-T cell therapies in difficult-to-treat cancers.
2026-06-01 13:09:33
Xenetic Biosciences Inc. presented preclinical data showing that DNase I enhances CAR-T cell expansion and antitumor efficacy in hematologic cancer models. The studies demonstrated that DNase I degrades extracellular DNA, preserves CAR-T cell function, and improves tumor control, suggesting it could be an effective adjunctive therapy. The company, which holds more cash than debt, is focused on advancing its systemic DNase program into clinical trials for solid tumors.
